137 related articles for article (PubMed ID: 15379950)
41. Clinical outcome of maximum androgen blockade using flutamide as second-line hormonal therapy for hormone-refractory prostate cancer.
Miyake H; Hara I; Eto H
BJU Int; 2005 Oct; 96(6):791-5. PubMed ID: 16153202
[TBL] [Abstract][Full Text] [Related]
42. Analysis of adverse event of interstitial lung disease in men with prostate cancer receiving hormone therapy using the Food and Drug Administration Adverse Event Reporting System.
Wu B; Shen P; Yin X; Yu L; Wu F; Chen C; Li J; Xu T
Br J Clin Pharmacol; 2023 Feb; 89(2):440-448. PubMed ID: 35349180
[TBL] [Abstract][Full Text] [Related]
43. Lack of methemoglobinemia with flutamide.
Schulz M; Schmoldt A; Donn F; Becker H
Ann Pharmacother; 2001 Jan; 35(1):21-5. PubMed ID: 11197580
[TBL] [Abstract][Full Text] [Related]
44. Frequency of flutamide induced hepatotoxicity in patients with prostate carcinoma.
Cetin M; Demirci D; Unal A; Altinbaş M; Güven M; Unlühizarci K
Hum Exp Toxicol; 1999 Mar; 18(3):137-40. PubMed ID: 10215102
[TBL] [Abstract][Full Text] [Related]
45. Adrenal androgen levels as predictors of outcome in castration-resistant prostate cancer patients treated with combined androgen blockade using flutamide as a second-line anti-androgen.
Narimoto K; Mizokami A; Izumi K; Mihara S; Sawada K; Sugata T; Shimamura M; Miyazaki K; Nishino A; Namiki M
Int J Urol; 2010 Apr; 17(4):337-45. PubMed ID: 20202011
[TBL] [Abstract][Full Text] [Related]
46. The use of flutamide as a single antiandrogen treatment for hormone-refractory prostate cancer.
Pitts WR
BJU Int; 2004 May; 93(7):1119-20. PubMed ID: 15142186
[No Abstract] [Full Text] [Related]
47. [Fatal interstitial lung disease associated with maximum androgen blockade].
Molina Mancero G; Picón X; Di Tullio F; Ernst G; Dezanzo P; Salvado A; Chertcoff JF
Rev Med Chil; 2016 Oct; 144(10):1356-1359. PubMed ID: 28074993
[TBL] [Abstract][Full Text] [Related]
48. Nilutamide response after flutamide failure in post-orchiectomy progressive prostate cancer.
Eastham JA; Sartor O
J Urol; 1998 Mar; 159(3):990. PubMed ID: 9474206
[No Abstract] [Full Text] [Related]
49. [The hepatotoxicity of flutamide].
Pogromov AP; Popova AM
Klin Med (Mosk); 1998; 76(7):56-8. PubMed ID: 9742783
[No Abstract] [Full Text] [Related]
50. [Hepatotoxicity of flutamide].
Wietzke P; Münke H; Hartmann H; Ramadori G
Z Gastroenterol; 1997 Aug; 35(8):631-5. PubMed ID: 9381745
[No Abstract] [Full Text] [Related]
51. [Flutamide-induced hepatic disorder and serum concentrations of flutamide and its metabolites in patients with prostate cancer].
Nakagawa Y; Koyama M; Matsumoto M
Hinyokika Kiyo; 1999 Dec; 45(12):821-6. PubMed ID: 10659414
[TBL] [Abstract][Full Text] [Related]
52. [Prostatic cancer with multiple pulmonary metastases treated successfully with hormonal therapy: a case report].
Fukuda M; Takashima H; Fuse H; Hirano S
Hinyokika Kiyo; 2002 Aug; 48(8):499-502. PubMed ID: 12243078
[TBL] [Abstract][Full Text] [Related]
53. The potential for normal tissue dose reduction with neoadjuvant hormonal therapy in conformal treatment planning for stage C prostate cancer.
Yang FE; Chen GT; Ray P; Vaida F; Chiru P; Hamilton RJ; Spelbring D; Abellera M; Vijayakumar S
Int J Radiat Oncol Biol Phys; 1995 Dec; 33(5):1009-17. PubMed ID: 7493827
[TBL] [Abstract][Full Text] [Related]
54. Experience with flutamide in previously untreated patients with advanced prostatic cancer.
Sogani PC; Whitmore WF
J Urol; 1979 Nov; 122(5):640-3. PubMed ID: 501817
[TBL] [Abstract][Full Text] [Related]
55. Localized amyloidosis of the seminal vesicle. Possible association with hormonally treated prostatic adenocarcinoma.
Unger PD; Wang Q; Gordon RE; Stock R; Stone N
Arch Pathol Lab Med; 1997 Dec; 121(12):1265-8. PubMed ID: 9431316
[TBL] [Abstract][Full Text] [Related]
56. Comparative study of the clinical efficacy of two dosing regimens of flutamide.
Thrasher JB; Deeths J; Bennett C; Iyer P; Dineen MK; Zhai S; Figg WD; McLeod DG
Mol Urol; 2000; 4(3):259-63;discussion 265. PubMed ID: 11062382
[TBL] [Abstract][Full Text] [Related]
57. Anemia in patients on combined androgen block therapy for prostate cancer.
Qian LX; Hua LX; Wu HF; Sui YG; Cheng SG; Zhang W; Li J; Wang XR
Asian J Androl; 2004 Dec; 6(4):383-4. PubMed ID: 15546035
[TBL] [Abstract][Full Text] [Related]
58. [Serum concentrations of flutamide and goserelin in a prostate cancer patient with obstructive nephropathy: a case report].
Nagayoshi J; Higashi T; Maruyama Y
Hinyokika Kiyo; 1999 Aug; 45(8):543-6. PubMed ID: 10500960
[TBL] [Abstract][Full Text] [Related]
59. Re: The effects of combined androgen blockade on cognitive function during the first cycle of intermittent androgen suppression in patients with prostate cancer.
Gardiner RA; Nicol DL; Green HJ; Yaxley J; Watson R; Mactaggart P; Headley BC; Swanson C; Pakenham KI
J Urol; 2004 Aug; 172(2):774; author reply 774-5. PubMed ID: 15247782
[No Abstract] [Full Text] [Related]
60. Steroid hormone withdrawal syndromes. Pathophysiology and clinical significance.
Kelly WK; Slovin S; Scher HI
Urol Clin North Am; 1997 May; 24(2):421-31. PubMed ID: 9126240
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
